Clinical Trials for Immunocore

Explore 10 clinical trials worldwide

Showing 1-10 of 10 trials

Active filters:Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruitingSponsor: Immunocore

Clinical Trials (10)

NCT06070012
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
PHASE2Recruiting
44 participants
Started: Mar 10, 2025 · Completed: Mar 31, 2030
1 condition2 sponsors1 location
NCT06627244
Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma
PHASE2Recruiting
30 participants
Started: Feb 14, 2025 · Completed: Feb 17, 2031
2 conditions2 sponsors1 location
NCT06246149
Adjuvant Tebentafusp in High Risk Ocular Melanoma
PHASE3Recruiting
290 participants
Started: Nov 11, 2024 · Completed: Nov 30, 2032
1 condition3 sponsors9 locations
NCT07156136
Study of IMC-P115C in Advanced PRAME-Positive Cancers
PHASE1Recruiting
140 participants
Started: Nov 7, 2024 · Completed: Aug 30, 2029
3 conditions1 sponsor13 locations
NCT06112314
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
PHASE3Recruiting
680 participants
Started: Jun 5, 2024 · Completed: Oct 16, 2027
1 condition1 sponsor174 locations
NCT06840119
Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers
PHASE1/PHASE2Recruiting
600 participants
Started: Jan 10, 2024 · Completed: Nov 30, 2027
2 conditions1 sponsor12 locations
NCT05549297
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
PHASE3Recruiting
540 participants
Started: Dec 19, 2022 · Completed: Jul 31, 2028
1 condition1 sponsor72 locations
NCT05315258
Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma
PHASE2Active, not recruiting
850 participants
Started: Jul 25, 2022 · Completed: Jun 30, 2027
2 conditions2 sponsors10 locations
NCT04262466
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
PHASE1/PHASE2Recruiting
727 participants
Started: Feb 25, 2020 · Completed: Aug 31, 2026
1 condition1 sponsor76 locations
NCT03070392
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
PHASE2Active, not recruiting
378 participants
Started: Oct 16, 2017 · Completed: Dec 31, 2025
1 condition1 sponsor57 locations